CD19 Assay Portfolio Service
Creative Biolabs has extensive experience in the field of immuno-oncology (IO). Our in-house experts specialize in the full spectrum of IO research and have the capability to provide comprehensive CD19 assay portfolio services. We are committed to supporting our customers' biopharmaceutical development pipeline with our expertise to achieve the success of the project.
The Background of CD19
CD19 (B-lymphocyte surface antigen B4) is a type I transmembrane glycoprotein of 95 kD, belonging to the immunoglobulin (Ig) superfamily. Alongside complement receptor CD21, CD81 (TAPA-1), as well as CD225, CD19 forms a multimolecular complex and functions as the dominant signaling component on the surface of mature B cells.
CD19 Targeted Therapeutics
CD19 antigen is considered to be a specific B-cell marker and has been a preferred target for the development of targeted therapeutics against B-cell malignancies due to the expression pattern on most B-cell malignancies. What is more, CD19 plays a crucial role in maintaining the balance between humoral, antigen-induced response and tolerance induction, and has been used in the therapy of autoimmune diseases. Currently, the rationale for CD19 as a molecular target in these disease settings includes the applications, such as CD19 antibodies, anti-CD19 CARs, ADCs and so on.
Fig.1 Therapeutic targeting of CD19. (Katz, 2014)
CBL’s Assay Portfolio Services
Creative Biolabs has robustly developed in vitro and in vivo platforms to provide reproducible CD19 targeted assays for our clients all over the world. We are dedicated to designing comprehensive research practices and handling high-quality studies to support your biopharmaceutical development pipeline. We can provide the following assays for our clients, but not limited to:
-
In Vitro Assays:
-
CD19-targeted leads screening;
-
Binding affinity test;
-
Epitope mapping;
-
Functional assay;
-
In Vivo Assays:
-
Model construction;
-
PK/PD study;
Creative Biolabs’ scientists are dedicated to bringing together years of valuable experience to help our clients shorten the project journey. For further details, please don't hesitate to contact us .
References
-
Yamada, S.; et al. Development of novel mouse monoclonal antibodies against human CD19. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2020, 39(2): 45-50.
-
Katz, B.Z.; Herishanu, Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. Leukemia & lymphoma. 2014, 55(5): 999-1006.
For Research Use Only | Not For Clinical Use
Download our brochure